Variable | Univariate | Multivariate | ||
HR (CI 95%) | p value | HR (CI 95%) | p value | |
Sex | 0.88 (0.51 - 1.54) | 0.65 | - | - |
Age (≤60 vs >60 years) | 0.65 (0.39 - 1.09) | 0.10 | - | - |
Cirrhosis (yes vs no) | 0.99 (0.31 - 3.19) | 0.99 | - | - |
Prior totreatmentSorafenib | 1.42 (0.84 - 2.38) | 0.18 |
|
|
Child-Pugh (B vs A) | 1.24 (0.56 - 2.75) | 0.59 |
|
|
ECOG-PS (2 vs <2) | 2.45 (1.01 - 5.91) | 0.04 |
|
|
BCLC (C vs B) | 1 (0.52 - 1.93) | 0.99 |
|
|
Numbers of nodules (3 vs ≤3) | 0.67 (0.36 - 1.26) | 0.21 |
|
|
Major nodule (≥2 vs <2 cm) | 0.24 (0.08 - 0.67) | <0.01 |
|
|
Extrahepatic metastasis (yes vs no) | 1.31 (0.79 - 2.17) | 0.29 |
|
|
Vascular invasion (yes vs no) | 1.23 (0.71 - 2.14) | 0.46 |
|
|
AFP (≤100 vs >100 ng/mL) | 2.91 (1.31 - 6.48) | <0.01 | 3.16 (1.56 - 6.41) | <0.01 |
Dermatologic adverse event (yes vs no) | 0.35 (0.2 - 0.62) | <0.01 | 0.44 (0.23 - 0.83) | <0.01 |
Diarrhea adverse event (yes vs no) | 0.53 (0.32 - 0.9) | <0.01 | - | - |
Time of sorafenib (≤6 vs >6 months) | 0.28 (0.16 - 0.5) | <0.01 | 0.25 (0.14 - 0.46) | <0.01 |